Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
Molecular Pharmacology Fast Forward. Published on August 1, 2005 as doi:10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

MOL 12963

Large-scale analysis of genes that alter sensitivity to the anti-cancer drug tirapazamine in *Saccharomyces cerevisiae.*

Karen Hellauer, Guillaume Lesage, Anne-Marie Sdicu and Bernard Turcotte

K. Hellauer and G. Lesage equally contributed to this work.

Departments of Medicine (K.H., B.T.), Biology (G.L., A.M.S), Biochemistry (B.T.), and Microbiology and Immunology (B.T.),

McGill University, Montréal, Québec, CANADA

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics.

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Running title:

Genes that alter sensitivity to the anti-cancer drug TPZ

Address correspondence to:

Bernard Turcotte, Room H7.83, Royal Victoria Hospital,

McGill University, 687 Pine Ave. West, Montréal, Québec, CANADA H3A 1A1

Tel. 514-934-1934 ext. 35046 (or 35047); FAX 514-982-0893;

E-mail: bernard.turcotte@mcgill.ca

34 text pages

5 tables (including 1 supplementary table)

6 figures (including 3 supplementary figures)

59 references

Abstract: 230 words

Introduction: 716 words

Discussion: 828 words

Non-standard abbreviations:

TPZ, tirapazamine

ORF, open reading frame

YEPD, yeast extract peptone dextrose

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

ABSTRACT

Tirapazamine (TPZ) is an anti-cancer drug that targets topoisomerase II. TPZ is preferentially active under hypoxic conditions. The drug itself is not harmful to cells, rather it is reduced to a toxic radical species by a NADPH cytochrome P450 oxidoreductase. Under aerobic conditions, the toxic compound reacts with oxygen to revert back to TPZ and a much less toxic radical species. We have used yeast (*Saccharomyces cerevisiae*) as a model to better understand the mechanism of action of TPZ. Overexpression of *NCP1*, encoding the yeast orthologue of the human P450 oxidoreductase, results in greatly increased sensitivity to TPZ. Similarly, overexpression of *TOP2* (encoding topoisomerase II) leads to hypersensitivity to TPZ suggesting that topoisomerase II is also a target of TPZ in yeast. Thus, our data show that yeast mimics human cells in terms of TPZ sensitivity. We have performed robot-aided screens for altered sensitivity to TPZ using a collection of approximately 4,600 haploid yeast deletion strains. We have identified 117 and 73 genes whose deletion results in increased or decreased resistance to TPZ, respectively. For example, cells lacking various DNA repair genes are hypersensitive to TPZ. In contrast, deletion of genes encoding some amino acid permeases results in cells that are resistant to TPZ. This suggests that permeases may be involved in intracellular uptake of TPZ. Our discoveries in yeast may help to better understand TPZ biology in humans.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

INTRODUCTION

Nonsurgical treatment of cancer includes radiotherapy and chemotherapy. A major drawback of these treatments is that they do not specifically target cancer cells. Approaches under current study include the use of hypoxic-selective drugs (reviewed by Brown and Giaccia, 1998; Rooseboom et al., 2004; Seddon et al., 2004). The approach is based on the fact that oxygen levels are generally lower in the center of a tumour because of poor vascularization (Brown and William, 2004). Since these hypoxic cells are generally more resistant to radiation and conventional chemotherapy (Gatenby et al., 1988; Hockel et al., 1993; Nordsmark et al., 1996; Okunieff et al., 1993; Teicher, 1994), drugs specifically active under low oxygen levels are of great interest for cancer treatment (Brown, 1999). The best prototype is probably 3-amino-1,2,4-benzotriazine 1,4 dioxide (also called tirapazamine or SR4233; hereafter referred to as TPZ). Phase II and III clinical trials have shown the efficacy of TPZ when used in combination with radiotherapy or chemotherapy (Bedikian et al., 1999; Craighead et al., 2000; Rischin et al., 2001; von Pawel et al., 2000).

The hypoxic toxicity of TPZ is thought to be due to the addition of one electron to TPZ by enzymatic reductases, yielding a radical species that causes single- and double strand DNA breaks leading to chromosome aberration and cell death (reviewed by Patterson et al., 1998). The radical species is unstable and, under normal oxygen levels, reacts with oxygen to revert back to TPZ and a much less toxic radical species (Lloyd et al., 1991). The exact mechanism of TPZ's action is not known. Under hypoxic conditions, a protonated neutral form of a TPZ nitroxide radical is formed, but there is no formal proof that this compound is responsible for the toxicity

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

(Patterson et al., 1998). The TPZ nitroxide is unstable and reacts with biomolecules such as DNA to form a non-toxic two-electron product called SR4317 (Lloyd et al., 1991). Interestingly, only a fraction (30-70%) of TPZ is converted to SR4317. This may explain why the rate of formation of SR4317 does not always correlate with toxicity (Siim et al., 1996). Recently, it was shown that TPZ inhibits DNA replication (Peters et al., 2001) and that it mediates its effect through topoisomerase II (Peters and Brown, 2002). Topoisomerase II unwinds DNA by introducing transient double stranded breaks. Therefore, TPZ treatment likely leads to covalent binding of the topoisomerase II α subunit to DNA, stabilizing topoisomerase II-induced double strand breaks and resulting in cell toxicity (Peters and Brown, 2002).

Under hypoxia, there is good evidence that NADPH cytochrome P450 oxidoreductase (E.C. 1.6.2.4) is involved in the metabolism of TPZ to a toxic compound (Chinje et al., 1999; Patterson et al., 1997; Saunders et al., 2000). Hypoxic sensitivity of human breast cancer cell lines to TPZ correlates with the expression of P450 oxidoreductase (Patterson et al., 1995). Furthermore, stable transfection of an expression vector encoding P450 oxidoreductase results in increased sensitivity to TPZ in human breast and lung cancer cell lines (Patterson et al., 1997; Saunders et al., 2000). In addition to P450 oxidoreductase, a nuclear enzyme is probably involved in the conversion of TPZ to a toxic molecule (Evans et al., 1998). Using a human lung cancer cell line, nuclei were found to be responsible for only 20% of the TPZ metabolism, but DNA damage was similar to what was observed for whole cells. These results suggest that an enzyme(s), other than the P450 oxidoreductase, is responsible for conversion of TPZ to a toxic compound. Thus, the relevant enzyme(s) appear to be nuclear unlike the oxidoreductase which is located at the membrane of the endoplasmic reticulum. In addition, other enzymes such as

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

cytochrome P450 and DT-diaphorase, can also metabolize TPZ (reviewed in (Brown and Giaccia, 1998; Patterson et al., 1998)).

Saccharomyces cerevisiae (referred to as yeast hereafter) has been a useful model organism to study various drugs (reviewed by Barret and Hill, 1998). In keeping with these results, our study shows that TPZ targets topoisomerase II and that overexpression of the *NCP1* gene (encoding an orthologue of the human P450 oxidoreductase) results in increased TPZ sensitivity in yeast cells. Screening of a panel of yeast deletion strains has allowed the identification of many genes that confer resistance or sensitivity to TPZ, including genes involved in DNA repair and amino acid transport.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

MATERIAL AND METHODS

Yeast strains

Wild-type strains used were BY4741 (MATa *his3Δ1 leu2Δ0 met15Δ0 ura3Δ0*) (Brachmann et al., 1998) and a derivative of BY4741, R1158 (Hughes et al., 2000) (MATa *his3Δ1 leu2Δ0 met15Δ0 URA3*::CMV-tTA). Strains yTH-NCP1 and yTH-TOP2 were obtained from Openbiosystems (Huntsville, AL, U.S.A.). Haploid deletion strains are derived from BY4741 (Winzeler et al., 1999) and were arrayed on sixteen 768-format plates (Tong et al., 2001).

Media and drug assays

Media were prepared according to Adams et al. (Adams et al., 1997). YEPD (yeast extract peptone dextrose) contained 1% yeast extract, 2% peptone, 2% glucose. TPZ was obtained from Sigma Chemical Co. (St.Louis, MO, U.S.A.) or Sanofi-Synthélabo (Malvern, PA, U.S.A.) and dissolved in 50% methanol or 50% ethanol. Anaerobic conditions were obtained using an anaerobic jar (Becton Dickinson) and gas pack (BBL GasPak Plus, Becton Dickinson). Anaerobic conditions were verified by using an anaerobic indicator (BBL, Becton Dickinson) and monitoring growth of the strict anaerobe *Clostridium tetanomorphum* (see *Supplementary Fig. S3*). Growth assays were all performed at 30^0C.

Ncp1 and Top2 overexpression

Haploid wild-type strain R1158 and strains carrying a doxycycline repressible promoter integrated at the *NCP1* or the *TOP2* loci were grown overnight in YEPD in the absence or the

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

presence of doxycycline (20 μg/ml; Sigma Chemical Co., St.Louis, MO, U.S.A.). Cells were serially diluted and spotted on YEPD plates containing various concentrations of TPZ and 20 μg/ml doxycycline for cells grown overnight in the presence of the antibiotic.

Western blot analysis of Top2

Extracts were prepared as described (Akache et al., 2004) and proteins were run on a 7.5% polyacrylamide gel. Western blot analysis was performed with a polyclonal antibody against *S. cerevisiae* Top2 (cat #2014,TopoGEN inc., Port Orange, Florida U.S.A.)

Screen for altered sensitivity to TPZ

Deletion strains were propagated on standard YEPD or YEPD supplemented with 200 μg/ml G418 (Invitrogen) using a colony picker (BioRad). Hypersensitive mutants were screened by pinning the deletion collection on YEPD supplemented with and without 300 μM TPZ, and then scoring the colony size after a 3.5 day incubation. Resistant mutants were screened by pinning the deletion collection on YEPD and then on YEPD supplemented with 750 μM TPZ. After 48 h, plates were replicated on fresh YEPD containing 750 μM TPZ and growth was scored after a 48 h incubation. Out of two screens for hypersensitive and a single screen for resistant mutants, 256 and 263 mutants were identified, respectively.

The sensitivity of these mutants was confirmed by the following spotting procedure: cells were grown in liquid YEPD to log-phase, diluted to an OD_{600} of 0.5, serially diluted 10-fold four times, and 5 μl were spotted on YEPD plates supplemented with and without 200 μM and 500 μM TPZ. After 2 days of incubation, growth of mutants in the presence or absence of TPZ was

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

scored and compared to that of the wild-type BY4741 strain. Mutants showing significant growth defect or absence of growth in the presence of 200 μM TPZ were scored as "- -" or "- - -", respectively. Mutants showing similar or more vigorous growth than the *fre1*Δ mutant in the presence of 500 μM TPZ were scored as "++" or "+++", respectively. Finally, 73 and 117 mutants exhibited hypersensitivity and resistance to TPZ, respectively.

Search for human proteins with yeast homologues involved in modulating TPZ sensitivity

A list of approximately 34,000 human protein sequences was obtained from Ensembl database (accessible from http://www.ensembl.org) and used as query in a search for homologues against the yeast proteome (approximately 6,000 protein sequences accessible from http://www.yeastgenome.org). We found about 26,000 human proteins matching a yeast protein sequence (E-value $\leq$ 0.001). Of this set, 614 human peptides showed significant homology to yeast product of genes involved in sensitivity or resistance to TPZ (data not shown). A partial list of these genes can be found in Tables 3 and 4.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

RESULTS

To determine if yeast can be used as a model for studying the mode of action of the anti-cancer drug TPZ, wild-type yeast cells were grown overnight under aerobic conditions, serially diluted, and spotted on plates containing increasing concentrations of TPZ. Cells were then grown under anaerobic or aerobic conditions for about 24 h (aerobia) or 48 h (anaerobia) (Fig. 1). Interestingly, TPZ was somewhat more toxic to cells grown under anaerobic conditions. For example, with 200 μM TPZ, growth was almost completely abolished under anaerobia while only a moderate effect was observed in the presence of oxygen (Fig. 1, panel E). Similar growth was observed in the absence of TPZ (panel A). However, the difference in TPZ toxicity of cells grown under aerobic and hypoxic conditions is much more pronounced in human tumour cell lines. For example, equal cell killing for human tumour cells grown under aerobic conditions requires approximately 300-times higher TPZ concentration when compared to hypoxic cells (Brown, 1993). The basis for this species difference is unknown but it may be related to the fact that yeast is a facultative aerobe (see below).

There is good evidence that the human NADPH oxidoreductase (EC 1.6.2.4) is responsible for metabolizing TPZ to a toxic compound (Chinje et al., 1999; Patterson et al., 1997; Saunders et al., 2000). We were interested in determining if a related enzyme would perform a similar function in yeast. The essential gene *NCP1* encodes the yeast orthologue of human P450 oxidoreductase. To study the involvement of *NCP1* in TPZ toxicity in yeast, the *NCP1* promoter of a haploid strain was replaced with a doxycycline repressible promoter

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

(Mnaimneh et al., 2004). Use of this promoter results in overexpression of the targeted gene in the absence of doxycycline and reduced expression in the presence of the antibiotic.

Overexpression of *NCP1* did not affect growth under aerobic or anaerobic conditions as compared to a wild-type strain (Fig. 1, panel A), while reduced expression of *NCP1* impaired growth only under anaerobic conditions (Fig. 1, panel B). The nearly normal aerobic growth under repressible conditions is probably due to leaky expression of *NCP1*, as observed for some other genes (Mnaimneh et al., 2004). Overexpression of *NCP1* was highly toxic to cells grown in the presence of TPZ (Fig. 1, panels C to F). This suggests that, as observed in human cells, high levels of P450 oxidoreductase result in increased production of a toxic metabolite (Patterson et al., 1997; Saunders et al., 2000). This provides further evidence that yeast NADPH oxidoreductase, as its human counterpart, is responsible, at least in part, to the conversion of TPZ to a toxic compound. Thus, yeast mimics human cells with regard to TPZ toxicity.

Since a recent study in animal cells shows that TPZ targets topoisomerase II (Peters and Brown, 2002), we tested if this enzyme also mediates TPZ toxicity in yeast cells. Overexpression of topoisomerase II results in hypersensitivity of yeast to some anti-cancer drugs (Nitiss et al., 1992) when tested in a DNA repair-deficient *rad52*Δ background. Since yeast topoisomerase II is encoded by the essential gene *TOP2* (Wang, 1996), we altered *TOP2* expression by using a doxycycline repressible promoter as described above for *NCP1*. Using this system, greatly increased expression of *TOP2* was observed with cells grown aerobically in the absence of doxycycline as compared to cells treated with doxycycline or a wild-type strain (Fig. 2A, left panel). Surprisingly, expression of *TOP2* in wild-type cells was greatly increased under

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

anaerobic conditions while the overexpression system gave only a modest increase in *TOP2* levels when compared to wild-type cells (Fig. 2A, right panel). Growth of these strains was similar when assayed under aerobic and anaerobic conditions in the presence or absence of doxycycline (Fig. 2B, panels A and B). Addition of doxycycline is likely not to lead to full repression of the promoter driving *TOP2* expression since *TOP2* is an essential gene (as suggested by the Western blot analysis). Under aerobic conditions, overexpression of *TOP2* in a wild-type background resulted in increased cell sensitivity to TPZ while cells with reduced expression of *TOP2* behaved as wild-type cells (Fig. 2B, compare panels C to F). This effect was less apparent under anaerobic conditions in agreement with the Western blot analysis of *TOP2* expression. These results suggest that topoisomerase II is a target of TPZ in yeast cells. Thus, our data show that yeast mimics human cells in terms of TPZ sensitivity.

Genome-wide screen for altered sensitivity to TPZ

The identification of yeast mutants (other than *NCP1* and *TOP2*) showing an altered sensitivity to TPZ should give insights into the mode of TPZ action and tools to design more effective drug treatments. As stated above, the difference of TPZ toxicity with regard to oxygen levels is much less pronounced in yeast than in human cells. It is well established that growth of yeast under anaerobic conditions results in global changes in gene expression (Becerra et al., 2002). For example, anaerobia results in cell wall and membrane remodeling (Aguilar-Uscanga and Francois, 2003). Altered TPZ entry into the cells may explain the relative weak sensitivity of yeast cells grown under anaerobic conditions. Anaerobicity also results in more rapid response to osmotic shock {Krantz, 2004 #3861] and in altered expression of genes encoding *NCP1* and cytochrome P450. Since oxygen levels have only a minor effect on TPZ sensitivity of yeast and

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

for easier manipulation of a large number of strains, we decided to perform a large-scale screen under aerobic conditions.

We performed robot-aided screens for altered sensitivity to TPZ using a collection of ~ 4,600 haploid deletion mutants corresponding to most non-essential yeast genes. Phenotypes were confirmed by individually spotting serial dilutions of deletion strains on TPZ and control plates (see *Supplementary Fig. S1*). Fig. 3 shows examples of strains that are resistant or sensitive to TPZ. In all, 73 strains were sensitive to the drug (Table 1) while 117 strains showed increased resistance to TPZ (see Table 2 for a list of the strongest resistance phenotypes and *Supplementary Table S1* for weaker resistance). Genes were grouped in categories according to their known or inferred function and are discussed accordingly. It should be stressed that we do not know what mechanism of TPZ action renders some deletion mutants sensitive to the drug. For example, the effect could be mediated by topoisomerase II or, alternatively, by DNA damage produced by a TPZ metabolite.

DNA repair and genome stability

Given that exposure to TPZ results in DNA damage, it was not unexpected that cells lacking various DNA repair genes would be hypersensitive to the drug. These genes encode members of the *RAD52* epistasis group (*RAD51*, *RAD52*, *RAD54*, *RAD55*, *RAD57*, *RAD59*), subunits of the MRX complex (*MRE11*, *RAD50* and *XRS2*), topoisomerase III (*TOP3*), factors involved in the repair of replication-dependent DNA damage (*ASF1*, *MMS1*, *MMS4*, *MMS22*, *MUS81*, *RAD5*, *RTT101*, *RTT107* and *UBC13*) and subunits of the nucleotide excision repairosome (*RAD10* and *RAD16*). In addition, four poorly characterized genes (*NCE4*, *RTT109*,

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

WSS1 and *YBR094W*), whose deletion leads to TPZ hypersensitivity, were included in this category because they show synthetic lethality with genes involved in DNA repair or genome stability. For example, a double deletion of *NCE4* and *TOP1* (encoding topoisomerase I) is lethal while *WSS1* and *YBR094W* show synthetic lethality with *SGS1*, a gene encoding a nucleolar DNA helicase involved in maintenance of genome integrity {Tong, 2004 #3825}. In contrast, deletion of the DNA repair genes *RAD18* or *DNL4* resulted in increased resistance to TPZ (Table 2). We do not know the reason for these observed resistance phenotypes.

Transporters

Interestingly, a number of resistant strains lack amino acid permeases such as Agp3 (Schreve and Garrett, 2004), Alp1 (Regenberg et al., 1999) or the choline permease, Hnm1. These results suggest that uptake of TPZ within the cell could be mediated by permeases (see discussion). In keeping with these results, genetic interactions suggest that Asi3 is a regulator of permease gene expression (Forsberg et al., 2001). Expression of putative permeases involved in TPZ uptake would be reduced in cells lacking Asi3 resulting in increased resistance to the drug.

Reductases and related proteins

As stated above, Ncp1 is very likely to be responsible for metabolizing TPZ to a toxic compound in yeast, as observed in mammalian cells. Interestingly, deletion of other reductase genes leads to resistance to TPZ. For example, cells lacking Fre1 are resistant to the drug. *FRE1* encodes a ferric and cupric reductase necessary for uptake of environmental $Cu2^{+}$ and $Fe3^{+}$ (Eide, 1998). Reduced copper is a substrate for the high affinity transporter Ctr1 and related transporters. Although Fre1 and Ctr1 are functionally linked, deletion of *CTR1* does not result in

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

resistance to TPZ, in contrast to what was observed for the anticancer drug cisplatin (Ishida et al., 2002; Lin et al., 2002; Nitiss, 2002). In addition, a strain lacking Utr1 shows increased resistance to TPZ. *UTR1* encodes a NAD kinase that enhances the activity of Fre1 (Lesuisse et al., 1996), an observation that may explain the phenotype of an *utr1*Δ strain. The other reductase identified in our screen is His4, a multifunctional enzyme bearing dehydrogenase activity and involved in histidine biosynthesis (Alifano et al., 1996).

Cell stress signaling and signal transduction

Deletion of genes required for resistance to oxidative stress such as *LYS7*, *SOD1* and *SOD2* leads to hypersensitivity. *SOD1* and *SOD2* encode superoxide dismutases and *LYS7* encodes a copper chaperone required for Sod1 activity. Hypersensitivity of strains lacking these stress genes is likely to be explained by the fact that metabolism of TPZ leads to the formation of a superoxide radical toxic to cells (Lloyd et al., 1991). In addition, mutants defective in the protein kinase C MAP-kinase pathway (*bck1* and *slt2*) or affected in signaling through multiple MAP-kinase pathways (*sit4*) show an increased TPZ sensitivity. In contrast, deletion of *HSP104* or *WSC2* leads to TPZ resistance. Wsc2 is a putative integral membrane protein and a stress response component required for cell wall integrity (Verna et al., 1997).

Vesicular transport

Deletion of genes involved in protein recycling to the endosomal compartment increases TPZ sensitivity. Included here are members of the ESCRT-I (*VPS26*), ESCRT-II (*SNF8* and *VPS25*) ECSRT-III (*SNF7*) complexes, which are involved in ubiquitin-mediated protein sorting to the vacuole, factors involved in protein sorting from the late-Golgi to the vacuole through AP-

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

3 transport vesicles (*VAM3* and *VPS41*), and components of the endosome-to-Golgi recycling pathway (*RIC1* and *WHI6*). In contrast, removal of three genes involved in ER-to-Golgi transport (*ERV41*, *SPO20*, *YOS9*) conferred resistance to TPZ.

Other categories

A set of deletion strains hypersensitive to a range of inhibitory compounds has been identified (Parsons et al., 2004). A number of these mutants also show hypersensitivity to TPZ. A first group is involved in the function of the vacuolar H^+-ATPase (*PPA1*, *TFP3*, *VMA4*, *VMA7* and *VMA10*). A second group of genes is involved in ergosterol biosynthesis (*ERG2*, *ERG3* and *ERG4*). The increased sensitivity to TPZ of the second group of deleted genes is likely due to altered plasma membrane fluidity. Similarly, other genes involved in lipid, fatty acid or sterol metabolism (*DPL1*, *EKI1*, *FAA3*, *PDR17*) resulted in resistance to TPZ when deleted. Removal of these genes may also alter plasma membrane fluidity and integrity, thereby restricting entry of TPZ into the cells. Other genes that modulate TPZ sensitivity are associated with transcription or RNA processing. For example, deletion of the RNA polymerase II subunit *RPB9*, components of the RNA-polymerase II mediator complex (*GAL11*, *PGD1*, *ROX3* and *SRB2*), subunit of the CCR4-NOT1 complex *POP2*, or transcriptional regulators (*DBF2*, *SPT10*, *SPT20* and *SWI4*) confers hypersensitivity to TPZ. These genes may be required for the transcription of TPZ resistance gene(s).

Relevance to human TPZ biology

We were interested to determine if the genes identified in our screen have human counterparts. A selected set of 30 human proteins showing significant homology to products of

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

yeast genes whose deletion leads to resistance to TPZ is shown in Table 3. Some of these human proteins have a role in cell proliferation (e.g. CLK1), cell morphogenesis (DAAM1 and 2) and signal transduction (e.g. HRAS). Others have been reported to exhibit altered expression in cancer cells. For example, OS-9 is amplified in sarcomas (Su et al., 1996). OS-9 is involved in oxygen-dependent degradation of the hypoxia inducible factor (Baek et al., 2005) and is associated with the ER membrane (Litovchick et al., 2002). Other human proteins, such as the KIST kinase or the XPR1 (Battini et al., 1999) may be involved in signaling and could play a role in TPZ sensing. Table 4 lists a selection of 40 human proteins sharing significant homology with products of yeast genes whose deletion confers TPZ hypersensitivity. These proteins may be important for resistance to TPZ in human cells. For example, removal of the manganese superoxide dismutase leads to TPZ hypersensitivity in both human (Wouters et al., 2001) and yeast cells (Table 1). Inhibition of processes such as microtubule cytoskeleton assembly, nuclear transport, protein synthesis, transport to the endosome, proton transport through V-type ATPase is likely to be synergistic with TPZ treatment in human cells as observed in yeast.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

DISCUSSION

Yeast has been a useful model organism in better understanding the mode of action of various drugs (reviewed in (Barret and Hill, 1998)). In this report, we show that yeast can also be used to study the anti-cancer drug TPZ. Yeast mimics animal cells with regard to TPZ toxicity. Firstly, overexpression of the *NCP1* gene (encoding a P450 oxidoreductase) results in a marked increased sensitivity to TPZ (Fig. 1), in analogy to human cells where overexpression of the P450 oxidoreductase results in increased TPZ toxicity (Chinje et al., 1999; Patterson et al., 1997; Saunders et al., 2000). Secondly, we provide good evidence that topoisomerase II is a target of TPZ in yeast (Fig. 2) as observed in animal cells (Peters and Brown, 2002). Thus, these observations reinforce the view that yeast can be used as a model to gain insights into the mechanism of action of TPZ.

We took advantage of the yeast system to perform a large-scale screen of non-essential genes that modulate sensitivity to TPZ (Tables 1 and 2, see also *Supplementary Table 1*). As other similar studies, our screen was not totally comprehensive; for example, essential genes were not tested and some non-essential genes modulating TPZ sensitivity may have not been identified in this study. However, our work led to the identification of one hundred and ninety deletion strains that showed an altered growth in the presence of TPZ., For example, a major class of mutants is related to DNA repair or genome stability, in agreement with the model of TPZ action. Similar results were obtained for screens with other anti-cancer agents such as cisplatin, oxaliplatin, mitomycin, and bleomycin (Aouida et al., 2004; Wu et al., 2004). *RAD1* and *RAD10* gene products form a complex and deletion of either gene results in similar

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

phenotypes (Prakash and Prakash, 2000). Surprisingly, a *rad1* deletion strain was not recovered in our screen while a *rad10* strain showed sensitivity to the drug. We manually spotted the *rad1* mutant and found it to be similar to that of a wild-type strain. Thus, the phenotype of a *rad10* mutant does not always appear to match that of a *rad1* mutant.

Besides Ncp1, two other reductases were found to confer resistance to TPZ when removed: Fre1 and His4. Both enzymes may metabolize TPZ to a toxic compound in analogy to Ncp1. To our knowledge, there is no human homologue of His4 ruling out the possibility that a human His4-like protein would be responsible for TPZ metabolism. However, various human proteins have domains that show similarity to Fre1 (Lambeth et al., 2000) and may modulate sensitivity to the drug.

Our screen identified three transporters encoding genes whose deletion enhances TPZ resistance: the choline permease gene *HNM1* and the amino-acid permease genes *AGP3* and *ALP1*. This suggests a role for these genes in TPZ uptake within the cells. Such membrane permeases have been previously shown to mediate the uptake and toxicity of other compounds. For example, Hnm1 is involved in the uptake of the alkylating agent nitrogen mustard, and an *hnm1*Δ mutant is resistant to this drug (Li and Brendel, 1994). Bleomycin action was found to be modulated by the level of the L-carnitine transporter Agp2. Drug uptake and toxicity were decreased and increased upon deletion and overexpression of *AGP2*, respectively (Aouida et al., 2004). Similarly, the copper transporter Ctr1 mediates cisplatin uptake in yeast and human cells (Ishida et al., 2002; Lin et al., 2002; Nitiss, 2002). Thus, it appears that TPZ, as other anti-cancer drugs, uses membrane transporters to enter the cells. Since related amino acid transporters are

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

found in humans (e.g. SLC7A2, Table 3), it will be interesting to determine if these transporters are involved in mediating uptake of TPZ in human cells.

This hypothesis is reinforced by our findings that deletion of a number of genes involved in ubiquitin-regulated protein trafficking alters the resistance to TPZ. Indeed, ubiquitination is known to regulate the transport of the general amino acid permease Gap1 (Soetens et al., 2001) and may regulate the transport of other amino acid permeases as well. According to this hypothesis, mutations affecting this ubiquitin-regulated endocytosis pathway (such as *snf7*, *snf8*, *vps25* or *vps26*) would perturb the turnover of permeases resulting in their accumulation at the plasma membrane. The TPZ hypersensitivity of these mutants may be explained by the resulting increased TPZ uptake into the cells. Conversely, a defect in forward permease trafficking (for example, *erv41* or *yos9*) would result in a decreased efficiency of TPZ entry into cells and, as a result, in an increased resistance to TPZ. In summary, we have shown that yeast can be used as a model to study the anti-cancer drug TPZ. This allowed the identification of many yeast genes that modulate sensitivity to the drug. These observations will be invaluable to further increase our understanding of the mode of action of TPZ in human cells. Moreover, our results suggest that yeast could be used to design derivatives of TPZ and related bioreductive drugs.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

ACKNOWLEDMENTS

We thank Sanofi-Synthelabo (Malvern, PA, U.S.A.) for providing TPZ. We are extremely grateful to Dr. Howard Bussey (Dept. of Biology, McGill University) for providing access to robotic facilities. We thank Dr. Ed Chan (McGill University) for advice and providing access to his anaerobic chamber for preliminary experiments. We thank Marc-André Sylvain, Edith Sirard and Stella Drury for input in this project. We are grateful to Sarah MacPherson for critical review of the manuscript. We also thank Drs. Fred Sherman, Simon Labbé, John White, Dindial Ramotar, and Stéphane Laporte for useful comments.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

REFERENCES

Adams A, Gottschling DE and Stearns T (1997) *Methods in yeast genetics*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.

Aguilar-Uscanga B and Francois JM (2003) A study of the yeast cell wall composition and structure in response to growth conditions and mode of cultivation. *Letters Appl. Microbiol.* **37**:268-274.

Akache B, MacPherson S, Sylvain MA and Turcotte B (2004) Complex interplay among regulators of drug resistance genes in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **279**:27855-60.

Alifano P, Fani R, Lio P, Lazcano A, Bazzicalupo M, Carlomagno MS and Bruni CB (1996) Histidine biosynthetic pathway and genes - structure, regulation, and evolution. *Microbiol. Rev.* **60**:44-69.

Aouida M, Page N, Leduc A, Peter M and Ramotar D (2004) A genome-wide screen in *Saccharomyces cerevisiae* reveals altered transport as a mechanism of resistance to the anticancer drug bleomycin. *Cancer Res.* **64**:1102-1109.

Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M, Chan DA, Giaccia AJ and Semenza GL (2005) OS-9 interacts with hypoxia-inducible factor 1α and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1α. *Mol. Cell* **17**:503-512.

Barret JM and Hill BT (1998) DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. *Anti-Cancer Drugs* **9**:105-23.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Battini JL, Rasko JEJ and Miller AD (1999) A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction. *Proc. Natl. Acad. Sci. U.S.A.* **96**:1385-1390.

Becerra M, Lombardia-Ferreira LJ, Hauser NC, Hoheisel JD, Tizon B and Cerdan ME (2002) The yeast transcriptome in aerobic and hypoxic conditions: effects of *hap1*, *rox1*, *rox3* and *srb10* deletions. *Mol. Microbiol.* **45**:265.

Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Plager C, McIntyre S and Viallet J (1999) Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. *Anti-Cancer Drugs* **10**:735-9.

Brachmann CB, Davies A, Cost GJ, Caputo E, Li J, Hieter P and Boeke JD (1998) Designer deletion strains derived from *Saccharomyces cerevisiae* S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. *Yeast* **14**:115-32.

Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. *Br. J. Cancer* **67**:1163-70.

Brown JM (1999) The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain memorial award lecture. *Cancer Res.* **59**:5863-70.

Brown JM and Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. *Cancer Res.* **58**:1408-16.

Brown JM and William WR (2004) Exploiting tumour hypoxia in cancer treatment. *Nature Rev. Cancer.* **4**:437-447.

Chinje EC, Patterson AV, Saunders MP, Lockyer SD, Harris AL and Stratford IJ (1999) Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines? *Br. J. Cancer* **81**:1127-33.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Craighead PS, Pearcey R and Stuart G (2000) A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. *Int. J. Radiat. Oncol. Biol. Phys.* **48**:791-795.

Eide DJ (1998) The molecular biology of metal ion transport in *Saccharomyces cerevisiae*. *Ann. Rev. Nutr.* **18**:441-469.

Evans JW, Yudoh K, Delahoussaye YM and Brown JM (1998) Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. *Cancer Res.* **58**:2098-101.

Forsberg H, Hammar M, Andreasson C, Moliner A and Ljungdahl PO (2001) Suppressors of *ssy1* and *ptr3* null mutations define novel amino acid sensor-independent genes in *Saccharomyces cerevisiae*. *Genetics* **158**:973-988.

Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH and Broder GJ (1988) Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* **14**:831-8.

Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG and Vaupel P (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. *Radiother. Oncol.* **26**:45-50.

Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai HY, He YDD, Kidd MJ, King AM, Meyer MR, Slade D, Lum PY, Stepaniants SB, Shoemaker DD, Gachotte D, Chakraburtty K, Simon J, Bard M and Friend SH (2000) Functional discovery via a compendium of expression profiles. *Cell* **102**:109-126.

Ishida S, Lee J, Thiele DJ and Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. *Proc. Natl. Acad. Sci. U.S.A.* **99**:14298-14302.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Lambeth JD, Cheng G, Arnold RS and Edens WA (2000) Novel homologs of gp91phox. *Trends Biochem. Sci.* **25**:459-61.

Lesuisse E, Casterassimon M and Labbe P (1996) Evidence for the *Saccharomyces cerevisiae* ferrireductase system being a multicomponent electron transport chain. *J. Biol. Chem.* **271**:13578-13583.

Li Z and Brendel M (1994) Sensitivity to nitrogen mustard in *Saccharomyces cerevisiae* is independently determined by regulated choline permease and DNA repair. *Mut. Res.* **315**:139-45.

Lin XJ, Okuda T, Holzer A and Howell SB (2002) The copper transporter *CTR1* regulates cisplatin uptake in Saccharomyces cerevisiae. *Mol. Pharmacol.* **62**:1154-1159.

Litovchick L, Friedmann E and Shaltiel S (2002) A selective interaction between OS-9 and the carboxyl-terminal tail of meprin beta. *J. Biol. Chem.* **277**:34413-34423.

Lloyd RV, Duling DR, Rumyantseva GV, Mason RP and Bridson PK (1991) Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. *Mol. Pharmacol.* **40**:440-5.

Mnaimneh S, Davierwala AP, Haynes J, Moffat J, Peng WT, Zhang W, Yang XQ, Pootoolal J, Chua G, Lopez A, Trochesset M, Morse D, Krogan NJ, Hiley SL, Li ZJ, Morris Q, Grigull J, Mitsakakis N, Roberts CJ, Greenblatt JF, Boone C, Kaiser CA, Andrews BJ and Hughes TR (2004) Exploration of essential gene functions via titratable promoter alleles. *Cell* **118**:31-44.

Nitiss JL (2002) A copper connection to the uptake of platinum anticancer drugs. *Proc. Natl. Acad. Sci. U.S.A.* **99**:13963-13965.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R and Wang JC (1992) Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. *Cancer Res.* **52**:4467-72.

Nordsmark M, Overgaard M and Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. *Radiother. Oncol.* **41**:31-9.

Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C and Vaupel P (1993) Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. *Int. J. Radiat. Oncol. Biol. Phys.* **26**:631-6.

Parsons AB, Brost RL, Ding H, Li Z, Zhang C, Sheikh B, Brown GW, Kane PM, Hughes TR and Boone C (2004) Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. *Nature Biotech.* **22**:62-9.

Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL and Stratford IJ (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). *Br. J. Cancer* **72**:1144-1150.

Patterson AV, Saunders MP, Chinje EC, Patterson LH and Stratford IJ (1998) Enzymology of tirapazamine metabolism: a review. *Anti-Cancer Drug Design* **13**:541-73.

Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL and Strafford IJ (1997) Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. *Br. J. Cancer* **76**:1338-47.

Peters KB and Brown JM (2002) Tirapazamine: A hypoxia-activated topoisomerase II poison. *Cancer Res.* **62**:5248-5253.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Peters KB, Wang HY, Brown JM and Iliakis G (2001) Inhibition of DNA replication by tirapazamine. *Cancer Res.* **61**:5425-5431.

Prakash S and Prakash L (2000) Nucleotide excision repair in yeast. *Mutation Res. - Fundamental Mol. Mech. Mutagenesis* **451**:13-24.

Regenberg B, During-Olsen L, Kielland-Brandt MC and Holmberg S (1999) Substrate specificity and gene expression of the amino-acid permeases in *Saccharomyces cerevisiae*. *Curr. Genet.* **36**:317-28.

Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, Sexton M, D'Costa I and von Roemeling R (2001) Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. *J. Clin. Oncol.* **19**:535-542.

Rooseboom M, Commandeur JNM and Vermeulen NPE (2004) Enzyme-catalyzed activation of anticancer prodrugs. *Pharmacol. Rev.* **56**:53-102.

Saunders MP, Patterson AV, Chinje EC, Harris AL and Stratford IJ (2000) NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. *Br. J. Cancer* **82**:651-6.

Schreve JL and Garrett JM (2004) Yeast Agp2p and Agp3p function as amino acid permeases in poor nutrient conditions. *Biochem. Biophys. Res. Comm.* **313**:745-751.

Seddon B, Kelland LR and Workman P (2004) Bioreductive prodrugs for cancer therapy, in *Meth. Mol. Med.* pp 515-42.

Siim BG, van Zijl PL and Brown JM (1996) Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. *Br. J. Cancer* **73**:952-60.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Soetens O, De Craene JO and André B (2001) Ubiquitin is required for sorting to the vacuole of the yeast general amino acid permease, Gap1. *J. Biol. Chem.* **276**:43949-57.

Su YA, Hutter CM, Trent JM and Meltzer PS (1996) Complete sequence analysis of a gene (Os-9) ubiquitously expressed in human tissues and amplified in sarcomas. *Mol. Carcinogenesis* **15**:270-275.

Teicher BA (1994) Hypoxia and drug resistance. *Cancer & Metastasis Reviews* **13**:139-68.

Tong AHY, Evangelista M, Parsons AB, Xu H, Bader GD, Page N, Robinson M, Raghibizadeh S, Hogue CWV, Bussey H, Andrews B, Tyers M and Boone C (2001) Systematic genetic analysis with ordered arrays of yeast deletion mutants. *Science* **294**:2364-2368.

Verna J, Lodder A, Lee K, Vagts A and Ballester R (1997) A family of genes required for maintenance of cell wall integrity and for the stress response in *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. U.S.A.* **94**:13804-13809.

von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J and Treat J (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. *J. Clin. Oncol.* **18**:1351-9.

Wang JC (1996) DNA Topoisomerases. *Ann. Rev. Biochem.* **65**:635-692.

Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, Bangham R, Benito R, Boeke JD, Bussey H, Chu AM, Connelly C, Davis K, Dietrich F, Dow SW, M ELB, Foury F, Friend SH, Gentalen E, Giaever G, Hegemann JH, Jones T, Laub M, Liao

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

H, Liebundguth N, Davis RW and et al. (1999) Functional characterization of the *S. cerevisiae* genome by gene deletion and parallel analysis. *Science* **285**:901-906.

Wouters BG, Delahoussaye YM, Evans JW, Birrell GW, Dorie MJ, Wang JL, MacDermed D, Chiu RK and Brown JM (2001) Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. *Cancer Res.* **61**:145-152.

Wu HI, Brown JA, Dorie MJ, Lazzeroni L and Brown JM (2004) Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. *Cancer Res.* **64**:3940-3948.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

FOOTNOTES

This work was supported by a grant from the Cancer Research Society (Montréal) to B.T. and the Canadian Institutes of Health Research to G.L. (principal investigator: Dr. Howard Bussey). B.T. was supported by a scholarship from the Fonds de la Recherche en Santé du Québec.

Bernard Turcotte, Room H7.83, Royal Victoria Hospital,

McGill University, 687 Pine Ave. West, Montréal, Québec, CANADA H3A 1A1

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

FIGURE LEGENDS

Figure 1

Overexpression of Ncp1 increases sensitivity to TPZ.

Wild-type strain R1158 ("WT") and yTH-NCP1 ("Tet-NCP1") were grown overnight under aerobic conditions in rich medium in the presence or absence of doxycycline to allow control of the expression of *NCP1*. Cells were serially diluted (left to right: approximately $1.25X10^4$, $2.5X10^3$, $5X10^2$ and $1X10^2$ cells) and spotted on rich plates containing ("+ DOX") or lacking ("- DOX") doxycycline. Concentrations of TPZ are indicated on the right part of the figure. Cells were grown aerobically (left panel) for about 24 h or anaerobically (right panel) for about 48 h.

Figure 2

Overexpression of topoisomerase II increases sensitivity to TPZ.

A) Wild-type strain R1158 ("WT") and yTH-TOP2 ("Tet-TOP2") were grown under aerobic or anaerobic conditions in the presence ("+ DOX") or absence ("- DOX") of doxycycline to an $O.D._{600}$ of 0.8-1.0. Total extracts were analyzed by immunoblotting with an anti-Top2 polyclonal antibody.

B) Wild-type strain R1158 ("WT") and yTH-TOP2 ("Tet-TOP2") were grown overnight under aerobic conditions in rich medium in the presence or absence of doxycycline to allow control of the expression of *TOP2*. Cells were serially diluted (left to right: approximately $1.25X10^4$, $2.5X10^3$, $5X10^2$ and $1X10^2$ cells) and spotted on rich plates containing ("+ DOX") or lacking ("-

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

DOX") doxycycline. Concentrations of TPZ are indicated on the right part of the figure. Cells were grown aerobically (left panel) for about 24 h or anaerobically (right panel) for about 48 h.

Figure 3

Examples of deletion strains exhibiting increased or decreased resistance to TPZ.

Wild-type strain (BY4741) and various deletion strains were grown overnight under aerobic conditions in YEPD to log-phase. Cells were serially diluted (left to right approximately $1.2X10^4$, $1.2X10^3$, $1.2X10^2$ and $1.2X10^1$ cells) and spotted on YEPD plates supplemented with and without 200 μM and 500 μM TPZ (as indicated in the top part of the Fig.). After a 48 h incubation, growth was scored as indicated on the right part of the Fig. ("ND": not determined).

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Table 1

Genes whose deletion confers hypersensitivity to TPZ.

Genes whose deletion results in hypersensitivity to TPZ are listed along with their systematic names ("ORF") and their cellular function (if known). Scores for strain sensitivities are also given:"---", hypersensitive strain; "- -", sensitive strain. See Fig. 3 for examples of relative sensitivities.

Gene	ORF	Score	Cellular function and Comment
			DNA REPAIR AND GENOME STABILITY
ASF1	*YJL115W*	---	Target of the Rad53-dependent DNA damage response
MMS1	*YPR164W*	---	Required for repair of replication-dependent DNA damage
MMS4	*YBR098W*	---	Required with Mus81 for repair of DNA damage by MMS
MMS22	*YLR320W*	---	Acts in a DNA repair pathway with Mms1
MRE11	*YMR224C*	---	Single-stranded endonuclease and double-stranded exonuclease required for double strand break repair
MUS81	*YDR386W*	---	Part of a complex with Rad54 and Mms4
NCE4	*YPL024W*	--	Synthetic interaction pattern suggests a role in DNA repair

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

RAD5	*YLR032W*	---	Single-stranded DNA-dependent ATPase involved in error-free DNA repair
RAD10	*YML095C*	---	Component of the nucleotide excision repairosome
RAD16	*YBR114W*	--	DNA helicase, subunit of the nucleotide excision repair factor *NEF4*
RAD50	*YNL250W*	---	Coiled-coil protein required for resection at double-stranded breaks and for DNA repair
RAD51	*YER095W*	---	Stimulates pairing and strand-exchange between homologous single-stranded and double-stranded DNA
RAD52	*YML032C*	---	Required for recombination and repair of X-ray damage
RAD54	*YGL163C*	---	DNA dependent ATPase required for X-ray damage repair
RAD55	*YDR076W*	---	With Rad57 promotes DNA strand exchange by Rad51 recombinase
RAD57	*YDR004W*	---	With Rad55 promotes DNA strand exchange by Rad51 recombinase
RAD59	*YDL059C*	---	Homologue of Rad52 involved in homologous recombination and DNA repair
RTT101	*YJL047C*	---	Ubiquitin protein ligase possibly involved in genomic stability
RTT107	*YHR154W*	--	Functions in DNA synthesis after DNA damage during S phase
RTT109	*YLL002W*	---	Involved in resistance to mutagens such as diepoxybutane and mitomycin C
TOP3	*YLR234W*	---	DNA topoisomerase III
UBC13	*YDR092W*	---	Ubiquitin-conjugating (E2) enzyme involved in Rad6-dependent post-replicative repair
WSS1	*YHR134W*	--	Involved in sensitivity to UV irradiation.
XRS2	*YDR369C*	---	Required for DNA-repair and meiotic recombination

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

	YBR094W	---	Synthetic interaction pattern suggests a role in DNA repair
			REDUCTASES AND RELATED PROTEINS
PRO2	*YOR323C*	---	Gamma-glutamyl phosphate reductase (phosphoglutamate dehydrogenase)
			CELL STRESS AND SIGNAL TRANSDUCTION
BCK1	*YJL095W*	---	Bypass requirement for protein kinase C homologue; MEKK
LYS7	*YMR038C*	---	Copper chaperone for superoxide dismutase Sod1
SIT4	*YDL047W*	---	Protein phosphatase of the PP2A family
SLT2	*YHR030C*	---	Protein kinase of MAP kinase family
SOD1	*YJR104C*	---	Cu, Zn superoxide dismutase
SOD2	*YHR008C*	--	Manganese superoxide dismutase, mitochondrial
			LIPID, FATTY ACID AND STEROL METABOLISM
ERG2	*YMR202W*	---	C-8 sterol isomerase, ergosterol biosynthesis enzyme
ERG3	*YLR056W*	--	C-5 sterol desaturase, ergosterol biosynthesis enzyme

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

ERG4	*YGL012W*	--	C-4(28) sterol reductase, ergosterol biosynthesis enzyme
			VESICULAR TRANSPORT
RIC1	*YLR039C*	---	In complex with Rgp1 to form as a guanyl-nucleotide exchange factor for Ypt6
SNF7	*YLR025W*	---	ESCRT-III subunit, functions in protein sorting to the pre-vacuolar endosome
SNF8	*YPL002C*	--	ESCRT-II subunit, functions in protein sorting to the pre-vacuolar endosome
VAM3	*YOR106W*	---	Syntaxin homologue (t-SNARE), required for vacuolar assembly
VPS25	*YJR102C*	--	ESCRT-II subunit, functions in protein sorting to the pre-vacuolar endosome
VPS28	*YPL065W*	--	Required for traffic to the vacuole through the endocytic and biosynthetic pathways
VPS41	*YDR080W*	---	Required for formation of AP-3 transport vesicles
WHI6	*YKR020W*	---	Class B vacuolar sorting protein
			VACUOLE
PPA1	*YHR026W*	--	Component of the V0 subcomplex of the vacuolar H+-ATPase
TFP3	*YPL234C*	---	Component of the V0 subcomplex of the vacuolar H+-ATPase
VMA4	*YOR332W*	---	Component of the V1 subcomplex of the vacuolar H+-ATPase

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

VMA7	*YGR020C*	---	Component of the V0 subcomplex of the vacuolar H+-ATPase
VMA10	*YHR039C-A*	---	Component of the V1 subcomplex of the vacuolar H+-ATPase

PROTEIN SYNTHESIS AND DEGRADATION

RPS4A	*YJR145C*	---	Ribosomal protein S4A
ZUO1	*YGR285C*	---	Zuotin, associates with Ssz1 to form the ribosome-associated complex

TRANSCRIPTION, RNA PROCESSING

DBF2	*YGR092W*	--	Serine/threonine protein kinase of the CCR4-NOT transcriptional complex
GAL11	*YOL051W*	---	Component of RNA polymerase II holoenzyme and Kornberg's mediator complex
PGD1	*YGL025C*	---	Component of RNA polymerase II holoenzyme and mediator subcomplex
POP2	*YNR052C*	---	Component of the CCR4 complex
ROX3	*YBL093C*	---	Component of RNA polymerase II holoenzyme and mediator subcomplex
RPB9	*YGL070C*	---	Non-essential subunit of RNA polymerase II
RSC2	*YLR357W*	--	Component of the abundant RSC complex involved in chromatin remodeling
SPT10	*YJL127C*	---	Amplifies the magnitude of transcriptional regulation at various loci

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

SPT20	*YOL148C*	---	Component of the histone acetyltransferase SAGA complex
SRB2	*YHR041C*	--	Component of RNA polymerase II holoenzyme and Kornberg's mediator complex
SWI4	*YER111C*	---	Transcription factor involved in cell cycle dependent gene expression
UAF30	*YOR295W*	--	Upstream activation factor complex component; synthetic lethal with *top1* mutation

OTHER FUNCTIONS

AKR1	*YDR264C*	---	Ankyrin repeat-containing protein, inhibitor of signaling in the pheromone pathway
ALF1	*YNL148C*	---	Alpha-tubulin folding cofactor B, assists in formation of the α-β-tubulin heterodimer
BEM1	*YBR200W*	---	SH3-domain protein maintaining Cdc42-Cdc24 at the bud tip
BEM4	*YPL161C*	---	Bud emergence protein that activates Cdc42
BUD20	*YLR074C*	--	Putative nuclear pore protein
CIK1	*YMR198W*	---	Spindle pole body associated protein
MDM20	*YOL076W*	---	Required for N-terminal acetylation of Tpm1 necessary for actin cable organization
MOG1	*YJR074W*	--	Involved in nuclear protein import, interacts with Gsp1
NUP188	*YML103C*	---	Nucleoporin
SLA1	*YBL007C*	---	Cytoskeleton assembly control protein

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

YNL171C	---	Overlaps with 3' of the essential gene *APC1/YNL172W*

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Table 2

Genes whose deletion enhances resistance to TPZ.

Genes whose deletion results in marked resistance to TPZ are listed along with their systematic names (‘ORF”) and their cellular function (if known). All strains listed were scored as “+++” for resistance. See Fig. 3 for examples of relative resistances. For a list of less resistant deletion strains, see *Supplementary Table 1*.

Gene	ORF	Cellular function and Comment
		DNA REPAIR AND GENOME STABILITY
DNL4	*YOR005C*	DNA ligase involved in non-homologous DNA end joining
RAD18	*YCR066W*	Zn finger protein, putative ATPase
		TRANSPORTERS
AGP3	*YFL055W*	Amino acid permease
ALP1	*YNL270C*	Arginine permease
ASI3	*YNL008C*	Involved regulation of amino acid permease gene expression

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

HNM1	*YGL077C*	Choline permease

REDUCTASES AND RELATED PROTEINS

FRE1	*YLR214W*	Ferric and cupric reductase
HIS4	*YCL030C*	Histidine biosynthesis enzyme
UTR1	*YJR049C*	NAD kinase enhances the activity of ferric/cupric reductase Fre1

CELL STRESS AND SIGNAL TRANSDUCTION

DIG1	*YPL049C*	MAP kinase-associated protein involved in regulation of invasive growth
HSP104	*YLL026W*	Heat shock protein
RAS1	*YOR101W*	GTP-binding protein involved in regulation of cAMP pathway
WSC2	*YNL283C*	Protein required for maintenance of cell wall integrity

LIPID, FATTY ACID AND STEROL METABOLISM

DPL1	*YDR294C*	Dihydrosphingosine-1-phosphate lyase
EKI1	*YDR147W*	Ethanolamine kinase I

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

FAA3	*YIL009W*	Acyl-CoA synthase
PDR17	*YNL264C*	Phosphatidylinositol transfer protein

VESICULAR TRANSPORT

ERV41	*YML067C*	COPII-coated vesicle component involved in ER to Golgi transport
SPO20	*YMR017W*	Subunit of the t-SNARE complex, required during sporulation
YOS9	*YDR057W*	Involved in ER to Golgi trafficking of GPI-anchored proteins

PROTEIN SYNTHESIS AND DEGRADATION

FYV10	*YIL097W*	Protein involved in the degradation of fructose-1,6-bisphosphatase
HRD1	*YOL013C*	E3 ubiquitin ligase required for degradation of misfolded proteins
RPS12	*YOR369C*	Ribosomal protein S12
UMP1	*YBR173C*	Proteasome maturation factor involved in proteasome assembly

TRANSCRIPTION AND RNA PROCESSING

CAF40	*YNL288W*	Strong similarity to *C. elegans* hypothetical protein

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

CTK2	*YJL006C*	RNA polymerase II C-terminal domain kinase beta subunit
HAA1	*YPR008W*	Transcription activator
MGA2	*YIR033W*	ER membrane protein involved in regulation of *OLE1* transcription
NTC20	*YBR188C*	Splicing factor
PAF1	*YBR279W*	Protein associated with RNA polymerase II
PUS4	*YNL292W*	Pseudouridine synthase
RNH1	*YMR234W*	Ribonuclease H, endonuclease that degrades RNA in RNA-DNA hybrids
RSE1	*YML049C*	U2 snRNP-associated protein involved in pre-mRNA splicing

OTHER FUNCTIONS

BDH1	*YAL060W*	Stereospecific (2R, 3R)-2,3-butanediol dehydrogenase
BNR1	*YIL159W*	Regulates reorganization of the actin cytoskeleton
DAL3	*YIR032C*	Ureidoglycolate hydrolase
ECM1	*YAL059W*	Protein involved in ribosome assembly
HOS2	*YGL194C*	Component of Set3 histone deacetylase
IBD2	*YNL164C*	Component of the *BUB2*-dependent spindle checkpoint pathway

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

KGD1	*YIL125W*	component of the E1 alpha-ketoglutarate dehydrogenase complex
MAM33	*YIL070C*	Mitochondrial protein required for normal respiratory growth
RNR3	*YIL066C*	Ribonucleotide reductase
SPO1	*YNL012W*	Meiosis-specific protein with similarity to phospholipase B enzymes
SYG1	*YIL047C*	Involved in G-protein coupled receptor signal transduction
TIR3	*YIL011W*	Member of the seripauperin and TIP1 family
	YBL083C	Overlaps with 3' part of *RHK1/YBL082C*
	YER049W	Component of NuA3 histone acetyltransferase complex

UNKNOWN AND POORLY CHARACTERIZED FUNCTIONS

AKL1	*YBR059C*	Serine/threonine protein kinase of unknown function
DOS2	*YDR068W*	Protein containing a BSD domain, may be involved in protein degradation
KNS1	*YLL019C*	Putative serine/threonine protein kinase
PHM8	*YER037W*	Protein of unknown function
RSM25	*YIL093C*	Protein of unknown function
UIP3	*YAR027W*	Protein with high similarity to *S. cerevisiae* Mst27, which binds COPI and

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

		COPII complexes, member of the duplication (DUP) family
SMY2	*YBR172C*	Protein of unknown function, suppresses myo2-66, sec22, bet1, sec16-3, spt15, and yrb1-51 mutants when overexpressed, may be involved in RNA splicing
	YCL023C	Protein of unknown function
	YDL156W	Protein containing three WD domains (WD-40 repeat), which may mediate protein-protein interactions, has moderate similarity to uncharacterized C. albicans Ipf2218
	YGR290W	Protein of unknown function
	YHR131C	Protein containing a pleckstrin homology (PH) domain, which mediate protein-protein and protein-lipid interactions, has low similarity to uncharacterized *S. cerevisiae YNL144*
	YIL161W	Protein of unknown function
	YJL163C	Hypothetical protein
	YJL218W	Protein with similarity to *E. coli* galactoside O-acetyltransferase
	YJR018W	Protein of unknown function
	YJR038C	Protein of unknown function

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

YJR056C	Protein of unknown function
YKL161C	Serine/threonine protein kinase with similarity to MAP kinases
YKR096W	Protein of unknown function, has high similarity to *S. cerevisiae YIL151*
YML050W	Protein of unknown function
YMR253C	Protein of unknown function, likely membrane protein
YNL144C	Protein of unknown function, has low similarity to uncharacterized *S. cerevisiae YHR131*
YNR024W	Protein of unknown function
YOL163W	Protein of unknown function
YOR044W	Protein of unknown function
YPR022C	Predicted transcription factor with two tandem C2H2-type zinc fingers, contains Q/N-rich regions which may mediate prion-like aggregation
YAL065C	Protein of unknown function, has high similarity to a region of flocculin (*S. cerevisiae FLO1*), which is a cell wall protein involved in flocculation

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Table 3

Selected human gene products with yeast homologues whose gene deletion enhances resistance to TPZ.

Human gene products are listed with their yeast homologues. E values (identical proteins would have an E value of zero) and the percentage of identities are also given.

Human gene product	Human gene product description	Yeast gene	E value	Identity (%)
	CELL DIFFERENTIATION, MORPHOGENESIS, SIGNALING			
DAAM1	Formin homolog involved in morphogenesis	*BNR1*	2E-18	24
DAAM2	Formin homolog involved in morphogenesis	*BNR1*	2E-18	23
MAEA	Anti-apoptotic factor mediating erythroblast attachment to macrophage	*FYV10*	1E-12	22
CLK1	Protein kinase involved in cell proliferation	*KNS1*	2E-68	40
HRAS	Transforming protein p21/H-Ras-1	*RAS1*	7E-49	63
MUC15	Mucin family member	*WSC2*	2E-07	22

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

TRANSPORT				
SLC7A2	Low-affinity cationic amino acid transporter	*AGP3*	1E-11	25
SLC7A1	High-affinity cationic amino acid transporter	*AGP3*	4E-08	24
SLC7A3	Cationic amino acid transporter	*AGP3*	1E-06	25
CDA14	Gene downregulated in prostate tumors	*ERV41*	1E-27	30
OS-9	Gene amplified in sarcomas	*YOS9*	8E-04	25
C2orf30		*YOS9*	3E-07	29
DNA REPAIR				
RQCD1	Transcription factor	*CAF40*	2E-89	61
LIG4	DNA ligase IV	*DNL4*	1E-75	25
TRUB1	TruB pseudouridine synthase homolog 1	*PUS4*	3E-23	33
TRUB2	TruB pseudouridine synthase homolog 2	*PUS4*	1E-06	27
RAD18	Postreplication repair protein RAD18	*RAD18*	1E-15	23
RNASEH1	Ribonuclease H1	*RNH1*	4E-09	25
RRM1	Ribonucleoside-diphosphate reductase M1 chain	*RNR3*	0	66

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

	OTHER			
SGPL1	Sphingosine-1-phosphate lyase 1, involved in cisplatin sensitivity in *D. discoideum*	*DPL1*	4E-108	41
ETNK1	Ethanolamine kinase	*EKI1*	5E-18	24
NP_061961	PAF domain containg protein	*PAF1*	1E-07	22
RPS12	40S ribosomal protein S12.	*RPS12*	3E-28	55
SF3B3	Splicing factor 3B subunit 3	*RSE1*	5E-61	27
XPR1	Xenotropic and polytropic retrovirus receptor	*SYG1*	3E-37	26
C13orf12		*UMP1*	8E-04	24
NP_079184		*YDL156W*	3E-21	24
NP_060703		*YER049W*	6E-20	32
KIST	Protein kinase interacting with stathmin	*YKL161C*	1E-13	29

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

Table 4

Selected human proteins sharing homology to yeast proteins whose gene deletion confers TPZ hypersensitivity.

Human gene products are listed with their yeast homologues. E values (identical proteins would have an E value of zero) and the percentage of identities are also given.

Human gene product	Human gene product description	Yeast gene	E value	Identity (%)
	CYTOSKELTON			
CKAP1	Tubulin-specific chaperone B	*ALF1*	4E-12	29
TTL	Tubulin-tyrosine ligase	*YBR094W*	4E-13	26
	NUCLEAR TRANSPORT, TRANSCRIPTION			
NP_057576	RAN guanine nucleotide release factor	*MOG1*	4E-12	29
NUP188	Nucloeoporin	*NUP188*	1E-04	22
POLR2I	RNA polymerase II subunit	*RPB9*	2E-26	45

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

SMARCD1	SWI/SNF complex 60 kDa subunit	*UAF30*	2E-07	36
	PROTEIN SYNTHESIS			
RPS4Y1	40S ribosomal protein S4, Y isoform 1	*RPS4A*	9E-109	71
RPS4Y2	40S ribosomal protein S4, Y isoform 2	*RPS4A*	7E-104	69
ZRF1	M-phase phosphoprotein	*ZUO1*	3E-39	43
	REDOX, SIGNALING			
ALDH18A1	γ-1-pyrroline-5-carboxylate synthetase	*PRO2*	2E-78	39
PPP6C	Serine/threonine protein phosphatase	*SIT4*	8E-115	65
MAPK7	Mitogen-activated protein kinase 7	*SLT2*	3E-93	46
SOD1	Cu/Zn superoxide dismutase	*SOD1*	5E-43	55
SOD2	mitochondrial Mn superoxide dismutase	*SOD2*	3E-49	46
	TRANSPORT			
C20orf178	Snf7 homologue	*SNF7*	2E-19	41
NP_689497	Alix3 interacting protein	*SNF7*	2E-18	41

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

HSPC134	Alix 2 interacting protein	*SNF7*	3E-17	38
EAP30	EAP30 subunit of ELL complex	*SNF8*	7E-37	37
NP_115729	VPS25 homolog	*VPS25*	5E-19	31
VPS28	Endosomal sorting protein	*VPS28*	2E-27	30
VPS41	Golgi to endosome sorting protein	*VPS41*	1E-63	25
	VACUOLE			
ATP6V0B	V-type H^+-ATPase V0 subunit	*PPA1*	1E-44	55
ATP6V1G1	V-type H^+-ATPase V1 subunit G1	*VMA10*	1E-07	38
ATP6V1G3	V-type H^+-ATPase V1 subunit G3	*VMA10*	7E-07	36
ATP6V1E2	V-type H^+-ATPase V1 subunit E2	*VMA4*	7E-19	35
ATP6V1E1	V-type H^+-ATPase V1 subunit E	*VMA4*	1E-18	33
ATP6V1F	V-type H^+-ATPase V1 subunit F	*VMA7*	8E-27	53
	DNA REPAIR			
ASF1B	Chromatin assembly factor	*ASF1*	5E-51	59
ASF1A	Chromatin assembly factor	*ASF1*	1E-40	61

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.

MRE11A	Double-strand break repair protein	*MRE11*	2E-108	41
MUS81	Crossover junction endonuclease	*MUS81*	2E-19	29
CNOT8	CCR4-NOT complex subunit 8	*POP2*	2E-51	37
ERCC1	DNA excision repair protein	*RAD10*	4E-13	30
RAG1	V(D)J recombination activating protein 1	*RAD16*	7E-04	31
SMARCA3	Helicase/ATPase of the SWI/SNF family	*RAD5*	2E-76	33
RAD50	RAD50 homolog isoform 1	*RAD50*	4E-149	28
RAD51	DNA repair protein RAD51 homolog 1	*RAD51*	5E-126	67
RAD52	DNA repair protein RAD52	*RAD52*	1E-40	49
RAD54L	DNA repair protein RAD54	*RAD54*	2E-165	50
TOP3A	DNA topoisomerase III alpha	*TOP3*	7E-125	42
UBE2N	E2 ubiquitin-conjugating enzyme	*UBC13*	6E-56	70

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 10, 2024

Molecular Pharmacology Fast Forward. Published on August 1, 2005 as DOI: 10.1124/mol.105.012963
This article has not been copyedited and formatted. The final version may differ from this version.


STRAIN:
TPZ:
DOX:
A
WT
Tet-NCP1
0 μM
-
B
WT
Tet-NCP1
0 μM
+
C
WT
Tet-NCP1
100 μM
-
D
WT
Tet-NCP1
100 μM
+
E
WT
Tet-NCP1
200 μM
-
F
WT
Tet-NCP1
200 μM
+
+O2
-O2

Fig. 1

Fig. 2


A
STRAIN:
WT
WT
Tet-TOP2
Tet-TOP2
WT
WT
Tet-TOP2
Tet-TOP2
DOX:
- + - + - + - +
160 kD
+ O2
- O2
B
STRAIN:
TPZ:
DOX:
A
WT
Tet-TOP2
0 μM -
B
WT
Tet-TOP2
0 μM +
C
WT
Tet-TOP2
100 μM -
D
WT
Tet-TOP2
100 μM +
E
WT
Tet-TOP2
200 μM -
F
WT
Tet-TOP2
200 μM +
+ O2
- O2


0
200 μM
500 μM
SCORE
WT
rad52Δ
ND
- - -
nce4Δ
ND
- -
agp3Δ
ND
+ + +
fre1Δ
ND
+ +
utr1Δ
ND
+ +